Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Possibilities of using Tanakan ® in therapy for generalized anxiety syndrome

Full Text:


The review considers the treatment of anxiety disorders (generalized anxiety and the anxious variant of adaptation disorders) with Tanakan® that is a standardized gingko biloba extract. The successful use of the drug in moderate anxiety states in elderly patients having cognitive disorders of cerebrovascular nature is now beyond question. However, the pronounced stimulating effect of Tanakan® requires that caution should be exercised when giving it in anxiety syndrome.

About the Author

D. Yu. Veltishchev
Moscow Research Institute of Psychiatry, Russian Agency for Health Care
Russian Federation


1. <div><p>Ansseau M., Dierick M., Buntinkx F. et al. High prevalence of mental disorders in primary care. J Affect Dis 2004; 78: 49-55.</p><p>Sansone R.A., Hendricks C.M., Gaither G.A. Prevalence of anxiety symptoms among a sample of outpatients in an internal medicine clinic: a pilot study. Depress Anx 2004; 19: 133-6.</p><p>Allgulander C., Bandelow B., Hollander E. et al. World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 2003; 8(Suppl. 1): 53-61.</p><p>Вельтищев Д.Ю. Диагностика и фармакотерапия тревожного варианта расстройств адаптации. Врач 2009; 5: 67-70.</p><p>Strain J.J., Smith G.C., Hammer J.S. et al. Adjustment disorder: a multisite study of its utilization and interventions in the consultation- liaison psychiatry setting. Gen Hosp Psychiatry 1998; 20: 139-49.</p><p>Semaan W., Hergueta T., Bloch J. et al. Er tude transversale de la prelvalence du trouble de l'adaptation avec anxieltel en meldecine gelneirale [Cross-sectional study of the prevalence of adjustment disorder with anxiety in general practice]. L'Encelphale 2001; 27: 238-44.</p><p>Chan D.C., Kasper J.D., Black B.S., Rabins P.V. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry 2003; 18: 174-82.</p><p>Forsell Y., Palmer K., Fratiglioni L. Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand 2003; 107(Suppl. 179): 25-8.</p><p>Lyketsos C.G., Lopez O., Jones B. et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the cardiovascular health study. J Am Med Assoc 2002; 288: 1475-83.</p><p>Montgomery S.A. Pregabalin for the treatment of GAD. Expert Opin Pharmacother 2006; 7(15): 2139-54.</p><p>Roy-Byrne P.P., Bystritsky A., Russo J. et al. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics 2005; 46: 117-22.</p><p>Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2002, Issue 4.</p><p>Le Bars P.L., Katz M.M., Berman N. et al. North American EGb Study Group. A placebo- controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. J Am Med Assoc 1997; 278: 1327-32.</p><p>Oken B.S., Storzbach D.M., Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-15.</p><p>Mix J.A., Crews W.D. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Human Psychopharm Clin Exp 2002; 17: 267-77.</p><p>Eckmann F., Schlag H. Kontrollierte Doppelblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskua Ërer Insuffizienz. Fortschritte Med 1982; 100: 1474-8.</p><p>Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 2003; 36(Suppl. 1): S56-S61.</p><p>Porsolt R.D., Martin P., Fromage S. et al. Antistress effects of EGb 761 in rodent models. In: Y . Cristen, J. Costentin, M. Lacour (eds). Effects of Ginkgo biloba extract (EGb 761) on the central nervous system. Elsevier,1992; 135-45.</p><p>Ward C.P., Redd K., Williams B.M. et al. Ginkgo biloba extract: cognitive enhancer of antistress buffer. Pharmacol Biochem Behav 2002; 72: 913-22.</p><p>Rapin J.R., Lamproglou I., Drieu K. Demonstration of the «anti-stress» activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen Pharmacol 1994; 25: 1009-16.</p><p>Marcilhac A., Dakine N., Bourhim N. et al. Effect of chronic administration of Ginkgo biloba extract or ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci 1998; 62: 2329-40.</p><p>Stroehle A., Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003; 36(Suppl. 3): S207-14.</p><p>Holsboer F. CRHR1 antagonists as novel treatment strategies. CNS Spectrums 2001; 6: 590-4.</p><p>Jezova D., Duncko R., Lassanova M. et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol 2002; 53: 337-48.</p><p>Woelk H., Arnoldt K.H., Kieser M., Hoerr R. Ginkgo biloba special extract in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2007; 41: 472-80.</p><p>Woelk H., Kapoula O., Lehrl S. et al. Behandlung von Angst-Patienten. Doppelblindstudie: Kava-Spezialextrakt versus Benzodiazepine. Zeitschrift fur Allgemeinmedizin 1993; 69: 271-7.</p><p>Allgulander C., Dahl A.A., Austin C. et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psych 2004; 161: 1642-9.</p><p>Meoni P., Hackett D., Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anx 2004; 19: 127-32.</p><p>Александровский Ю.А. Пограничные психические расстройства. М., 2000; 496.</p><p>Краснов В.Н., Вельтищев Д.Ю. Неврастения как вариант астенического синдрома: фармакотерапевтический анализ на модели терапии танаканом. Журн. неврол. и психиатр. им. С.С. Корсакова 1999; 99(7): 37-40.</p><p>Незнамов Г.Г., Телешова Е.С., Сюняков С.А. и др. Влияние танакана на психофизиологическое состояние больных с астеническими расстройствами. Экспер. клин. психофармакол. 2002; 1: 22-8.</p><p>Akiskal H.S. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand 1998; 98(Suppl. 3): 66-73.</p><p>Angst J., Gamma A., Bienvenu O. et al. Varying temporal criteria for generalized anxiety disorder: prevalence and clinical characteristics in a young age cohort. Psychol Med 2006; 36(9): 1283-92.</p><p>Cieza A., Maier P., Poeppel E. Effects of Ginkgo biloba on mental functioning in healthy volunteers. Arch Med Res 2003; 34: 373-81.</p><p>de Jonghe F., Swinkels J., Tuynman-Qua H. A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry 1989; 22: 266-71.</p></div><br />


For citations:

Veltishchev D.Yu. Possibilities of using Tanakan ® in therapy for generalized anxiety syndrome. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(2):88-91. (In Russ.)

Views: 831

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)